{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Infectious+Disorder&page=17",
    "query": {
      "condition": "Infectious Disorder",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 8612,
    "total_pages": 862,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Infectious+Disorder&page=18&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Infectious+Disorder&page=16&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T04:58:36.978Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02215707",
      "title": "A Clinical Trial of the PfSPZ Vaccine Administered by Direct Venous Inoculation in Healthy Malaria-Naïve Adults: Heterologous vs. Homologous Controlled Human Malaria Infection and Reduction in Number of Doses",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "PfSPZ Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanaria Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 67,
      "start_date": "2014-06",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2018-06-29",
      "last_synced_at": "2026-10-23T04:58:36.978Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02215707"
    },
    {
      "nct_id": "NCT01277692",
      "title": "A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "GSK2336805 10mg",
          "type": "DRUG"
        },
        {
          "name": "GSK2336805 30mg",
          "type": "DRUG"
        },
        {
          "name": "GSK2236805 100mg",
          "type": "DRUG"
        },
        {
          "name": "GSK2236805 200mg",
          "type": "DRUG"
        },
        {
          "name": "GSK2236805 10mg",
          "type": "DRUG"
        },
        {
          "name": "GSK2236805 dose to be determined up to 100mg",
          "type": "DRUG"
        },
        {
          "name": "GSK2236805 5mg",
          "type": "DRUG"
        },
        {
          "name": "GSK2236805 30mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 58,
      "start_date": "2010-11-03",
      "completion_date": "2011-05-09",
      "has_results": false,
      "last_update_posted_date": "2017-06-28",
      "last_synced_at": "2026-10-23T04:58:36.978Z",
      "location_count": 3,
      "location_summary": "Chula Vista, California • Lenexa, Kansas • Willingboro, New Jersey",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Willingboro",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01277692"
    },
    {
      "nct_id": "NCT00200369",
      "title": "Characterization of the Adherence Threshold for HIV Suppression of a Kaletra-based Regimen",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "MEMS cap",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Montefiore Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2004-05",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2009-11-05",
      "last_synced_at": "2026-10-23T04:58:36.978Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00200369"
    },
    {
      "nct_id": "NCT06380166",
      "title": "Hepatitis C Lab Testing Comparison Study",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Hepatitis C core antigen",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "HealthPartners Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2024-07-24",
      "completion_date": "2024-12-06",
      "has_results": false,
      "last_update_posted_date": "2025-01-06",
      "last_synced_at": "2026-10-23T04:58:36.978Z",
      "location_count": 1,
      "location_summary": "Bloomington, Minnesota",
      "locations": [
        {
          "city": "Bloomington",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06380166"
    },
    {
      "nct_id": "NCT00896051",
      "title": "TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections",
        "Acquired Immunodeficiency Syndrome"
      ],
      "interventions": [
        {
          "name": "Atazanavir (ATV) 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Atazanavir (ATV) 400 mg",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir (rtv) 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs)",
          "type": "DRUG"
        },
        {
          "name": "Etravirine (ETR) 200 mg",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir disoproxil fumarate (TDF) 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen R&D Ireland",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2009-08",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2013-09-30",
      "last_synced_at": "2026-10-23T04:58:36.978Z",
      "location_count": 10,
      "location_summary": "Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 7 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00896051"
    },
    {
      "nct_id": "NCT03473002",
      "title": "A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Antiviral Prophylaxis",
        "Respiratory Syncytial Virus Infection"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "SeVRSV Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 21,
      "start_date": "2018-05-16",
      "completion_date": "2019-02-14",
      "has_results": false,
      "last_update_posted_date": "2019-03-01",
      "last_synced_at": "2026-10-23T04:58:36.978Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03473002"
    },
    {
      "nct_id": "NCT00751153",
      "title": "Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Raltegravir and Atazanavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Peter J. Ruane, M.D., Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2008-03",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2008-10-09",
      "last_synced_at": "2026-10-23T04:58:36.978Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00751153"
    },
    {
      "nct_id": "NCT00753467",
      "title": "A Phase II Study to Determine the Safety and Efficacy of Interferon-gamma in Patients With Chronic Hepatitis B",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis B"
      ],
      "interventions": [
        {
          "name": "IFN-γ 1b (Actimmune)",
          "type": "DRUG"
        },
        {
          "name": "Adefovir dipivoxil",
          "type": "DRUG"
        },
        {
          "name": "IFN-γ 1b and Adefovir dipivoxil combination",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Huntington Medical Research Institutes",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 30,
      "start_date": "2008-09",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2010-10-21",
      "last_synced_at": "2026-10-23T04:58:36.978Z",
      "location_count": 1,
      "location_summary": "Pasadena, California",
      "locations": [
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00753467"
    },
    {
      "nct_id": "NCT04809636",
      "title": "Evaluating the Impact of Incentives on Clinical Trial Participation",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hiv",
        "Aging",
        "Incentives"
      ],
      "interventions": [
        {
          "name": "This is not an interventional study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, Riverside",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 360,
      "start_date": "2021-01-01",
      "completion_date": "2022-12-31",
      "has_results": false,
      "last_update_posted_date": "2021-03-22",
      "last_synced_at": "2026-10-23T04:58:36.978Z",
      "location_count": 1,
      "location_summary": "Riverside, California",
      "locations": [
        {
          "city": "Riverside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04809636"
    },
    {
      "nct_id": "NCT00004739",
      "title": "The Metabolic Effects of Protease Inhibitors in HIV Infected Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Antiretroviral therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Center for Research Resources (NCRR)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "7 Years to 18 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-23T04:58:36.978Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004739"
    }
  ]
}